Core Viewpoint - The National Healthcare Security Administration (NHSA) is promoting the transformation of precision medicine, leading to a strong performance in the medical sector of both A-shares and Hong Kong stocks on January 21 [1][7]. Group 1: Market Performance - In the Hong Kong market, MicroPort Scientific Corporation (MicroPort) surged over 12%, leading the gains, while Alibaba Health increased by over 3% [1][7]. - The Hong Kong medical ETF, Huabao (159137), reached a peak of 1.78% during trading [1][7]. - A-shares also saw a recovery, with Meiyuan Health and Kingmed Diagnostics rising over 3%, and Yuyue Medical and Yingke Medical both increasing over 2% [3][9]. Group 2: ETF Insights - The largest medical ETF in the market (512170) rose over 1.3%, recovering its six-month moving average, with significant capital inflow of over 270 million yuan in net subscriptions [3][9]. - As of January 20, 2026, the medical ETF fund size is 26 billion yuan, making it the largest among medical ETFs in the market [5][11]. Group 3: Policy Developments - The NHSA issued the "Guidelines for the Pricing of Surgical and Treatment Auxiliary Medical Services (Trial)," standardizing pricing for robotic surgeries and remote surgical assistance [5][11]. - The guidelines include 37 pricing items, 5 additional charges, and 1 expansion item, covering various fields such as 3D reconstruction and remote surgery [5][11]. - Notable highlights in pathology services include the establishment of a separate pricing item for pathology diagnosis and the inclusion of digital pathology slice storage in the pricing structure [5][11].

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index rising by 0.55% and several constituent stocks showing significant gains [1] - The Medical Innovation ETF has seen continuous net inflows over the past three days, with a maximum single-day net inflow of 6.0262 million and a total of 11.2443 million, averaging 3.7481 million per day [1] - The National Healthcare Security Administration issued a guideline aimed at standardizing pricing for surgical and treatment auxiliary services, promoting a shift from traditional treatment to precision medicine [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the sector [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray Medical, and others, accounting for 63.75% of the total index weight [2]

Summary of Conference Call on Northeast Medical Health Industry Industry Overview - The conference call discusses the Northeast Medical Health industry, specifically focusing on the recent developments in surgical robotics and innovative medical technologies. Key Points and Arguments 1. **National Pricing Guidelines**: On January 20, the National Healthcare Security Administration (NHSA) released the "Guidelines for the Establishment of Pricing Projects for Surgical and Treatment Auxiliary Medical Services (Trial)" which establishes a unified pricing framework for surgical robots, energy equipment consumables, and remote surgery technologies across the country [1][3]. 2. **Provincial Implementation Timeline**: Historical data suggests that it typically takes between six months to a year for provinces to implement specific projects and pricing after the NHSA's announcement [2]. 3. **Benefits of Pricing Directory**: The establishment of a clear pricing directory is expected to facilitate the entry of innovative devices into hospitals and increase the sales volume of consumables [4]. 4. **Impact on Clinical Promotion**: Previously, the need for medical institutions to apply for self-pricing or provincial pricing led to reduced enthusiasm for clinical promotion. The new pricing directory aims to streamline the final pricing model across provinces, enhancing the accessibility of advanced medical technologies and promoting a shift from traditional to precision medicine [5]. 5. **Tiered Pricing System for Surgical Robots**: A tiered pricing system based on the clinical value and participation level of surgical robots has been introduced. Prices will be set in three tiers: navigation, participation in execution, and precise execution. The guidelines also include specific consumables in the pricing structure [5]. 6. **Independent Pricing for Remote Surgery**: Remote surgery has been given independent pricing status, which is expected to benefit leading hospitals and increase surgical volumes [6]. 7. **Clarification on Consumable Charges**: The guidelines clarify the charging logic for disposable and reusable consumables, stating that disposable consumables will be sold at zero markup, while reusable consumables will incur an auxiliary operation fee [7]. Key Beneficiaries 1. **MicroPort Robotics**: A leading domestic surgical robot company with over 160 cumulative orders for laparoscopic robots expected by December 2025. The company is positioned to capitalize on the commercialization of surgical robots and expand market share through innovative procedures [8]. 2. **JinFeng Medical**: Among the top two domestic surgical robot manufacturers, it is rapidly increasing the volume of multi-port and single-port laparoscopic robots, leading in domestic procurement bids [8]. 3. **Tianzhihang**: A leader in orthopedic surgical robots, the company has developed a comprehensive business model that includes equipment, consumables, and technical services [8]. 4. **Sanyou Medical**: Focused on developing three-arm spinal surgical robots and ultrasonic bone knives, benefiting from the new pricing regulations for energy equipment consumables [8]. 5. **Aikang Medical**: Set to launch a second-generation knee joint surgical robot in collaboration with Peking University Third Hospital, aiming to provide a complete digital orthopedic solution [8]. 6. **Chunli Medical**: Innovating with handheld robotic technology, the company plans to establish multiple surgical training centers overseas to accelerate international expansion [9].

微创机器人-B(02252)再涨超7%，截至发稿，涨7.21%，报28.26港元，成交额7265.63万港元。 值得注意的是，微创机器人此前公告，综合订单方面，经本集团内部初步统计，本集团旗下腔镜、骨 科、血管介入核心产品的综合订单量累计突破230台。其中，核心产品图迈腔镜手术机器人(图迈)于全 球范围内累计商业化订单超过160台，含今年新获订单近120台。根据公开统计数据，图迈2025年全球订 单量已跻身全球前二。 消息面上，国家医保局近日印发《手术与治疗辅助操作类医疗服务价格项目立项指南（试行）》，聚焦 3D打印、手术机器人、远程手术等前沿医疗技术，统一规范了37项价格项目、5项加收项及1项扩展 项，旨在以价格机制引领医疗技术升级，推动"传统治疗"向"精准医疗"转型。 ...

消息面上，国家医保局近日印发《手术与治疗辅助操作类医疗服务价格项目立项指南（试行）》，聚焦 3D打印、手术机器人、远程手术等前沿医疗技术，统一规范了37项价格项目、5项加收项及1项扩展 项，旨在以价格机制引领医疗技术升级，推动"传统治疗"向"精准医疗"转型。 值得注意的是，微创机器人此前公告，综合订单方面，经本集团内部初步统计，本集团旗下腔镜、骨 科、血管介入核心产品的综合订单量累计突破230台。其中，核心产品图迈腔镜手术机器人(图迈)于全 球范围内累计商业化订单超过160台，含今年新获订单近120台。根据公开统计数据，图迈2025年全球订 单量已跻身全球前二。 智通财经APP获悉，微创机器人-B(02252)再涨超7%，截至发稿，涨7.21%，报28.26港元，成交额 7265.63万港元。 ...

Core Insights - The market share of domestic surgical robots in China has increased from 32.61% in 2023 to 48.89% in 2024, indicating significant growth in the sector [1] - Despite advancements, the utilization rate of robots in surgeries in China is only 6.33%, compared to 42% in the United States, highlighting room for improvement in the clinical application of surgical robots [1] Group 1: Changes in Pricing Logic - The previous pricing model for surgical robots was based on factors like surgical approach and brand, leading to unclear charges and increased patient burden [2] - The new guidelines introduce three pricing categories: navigation, participation in execution, and precise execution, allowing for a more transparent and fair pricing structure [2] - This "pay for performance" approach rewards robots that demonstrate higher participation and clinical value, potentially excluding less effective products from benefiting financially [2] Group 2: Clinical Value and Market Recognition - The guidelines acknowledge the clinical value of surgical robots, which may shorten the adoption cycle for new technologies and enhance market recognition for self-developed products [3] - Companies like Shenzhen Precision Medical Technology have successfully completed over 14,000 clinical surgeries with their robotic systems, reinforcing the importance of clinical validation [3] Group 3: Expansion of Precision Surgery - The guidelines aim to broaden the application of precision surgeries by enabling remote surgical assistance, which can be particularly beneficial for patients in remote areas [4] - The introduction of a "remote surgical assistance fee" will facilitate the use of surgical robots in telemedicine, allowing experts in resource-rich areas to assist patients elsewhere [4] - The national health authority plans to unify medical service pricing across the country, ensuring access to high-quality and affordable medical services for the public [4]

第三项是支持民营企业债券风险分担机制。这也是一项新政策。中央财政专门安排风险分担资金，与央行现有政策协同，为民营企业和私募股权投资机构发 行债券提供增信支持，代偿投资人部分损失。 【钛媒体综合】今年的首场国务院常务会议研究推出财政金融促内需一揽子政策，社会上高度关注。1月20日，财政部副部长廖岷在国新办新闻发布会上介 绍了一揽子政策的要点内容，概括为"一个目标""两个重点""三个原则"和"六项政策"。截至目前，这些政策已经陆续发布。 第一项是中小微企业贷款贴息政策。这是支持中小微民营企业发展的一项新政策。主要是对相关领域企业贷款予以贴息，重点包括新能源汽车、工业机器 人、医疗装备、移动通讯设备等14个重点产业链及上下游产业，以及科技、物流、信息和软件等生产性服务领域，还有农林牧副渔等领域。贴息为贷款总额 的1.5个百分点，最长贴息期2年，可享受贴息政策的单户贷款额度上限是5000万元。 第二项是民间投资专项担保计划。这项新政策主要是为中小微民营企业贷款提供担保，符合条件的中小微民营企业，因为生产场景的拓展、改造、升级，以 及改扩建厂房、店面装修等生产经营活动需要的中长期贷款，均可获得支持。单家企业可享受担保的 ...

Group 1 - The National Healthcare Security Administration (NHSA) has issued a guideline for pricing surgical and treatment auxiliary medical services, consolidating existing price projects into 37 items, which aims to establish a pricing management framework for robotic and remote surgeries [1][2] - The guideline focuses on cutting-edge medical technologies such as 3D printing, imaging enhancement, energy devices, intraoperative imaging guidance, and robotic surgeries, promoting a shift from traditional treatment to precision medicine [2][3] - The pricing structure includes different tiers for surgical robots based on their participation and clinical value, allowing for higher fees for more advanced and precise robotic surgeries [3] Group 2 - The introduction of the guideline is expected to stimulate research and development enthusiasm among medical device companies, shortening the technology promotion cycle and driving down costs in the domestic supply chain [4][5] - Companies like Medtronic and others are committed to introducing innovative technologies to provide high-quality and affordable medical solutions for Chinese patients following the guideline's implementation [6] - The sales data for surgical robots indicates a slight decline in total sales but an increase in specific segments, highlighting the importance of clinical value in commercializing these technologies [7]

Core Insights - The National Healthcare Security Administration (NHSA) has issued a guideline for pricing surgical and treatment auxiliary medical services, consolidating existing pricing projects into 37 items, which aims to establish a pricing management framework for robotic and remote surgeries [1][2] Group 1: Pricing Framework - The guideline focuses on advanced medical technologies such as 3D printing, imaging enhancement, energy devices, intraoperative imaging guidance, robotic arms, and remote surgeries, leading to a unified pricing structure [1] - It introduces a tiered pricing model for surgical robots based on their participation level and clinical value, allowing for higher fees for more advanced robotic systems [2] - The NHSA will guide local healthcare authorities to set reasonable pricing standards, ensuring accessibility for patients while considering the costs of robotic surgeries [2] Group 2: Industry Impact - The release of the guideline is expected to invigorate research and development among domestic medical device companies, shortening the technology promotion cycle and reducing costs in the supply chain [3] - Companies like Shanghai MicroPort Medical Robotics and Medtronic express optimism that the guideline will facilitate the entry of high-quality surgical robots into the market, benefiting more patients [3] - The clinical value of surgical robots is seen as a key factor for commercialization, with a reported increase in sales and revenue for robotic surgeries, indicating a growing market [3][4] Group 3: Market Trends - In the first 11 months of 2025, surgical robot sales reached 332 units, a year-on-year increase of 3.75%, with total sales amounting to 2.973 billion yuan, showing a slight decline of 0.87% [3] - Laparoscopic surgical robots dominate the market, accounting for 35.8% of total sales volume and 61.3% of sales revenue, while orthopedic surgical robots have shown significant growth in both sales volume and revenue [3] - The NHSA's establishment of a unified pricing framework for robotic surgeries is anticipated to be a breakthrough for commercialization in the industry [3]

Core Viewpoint - The National Healthcare Security Administration of China is promoting the large-scale application of surgical robotic arms by establishing a new pricing project for "remote surgical assistance" to enhance the integration of advanced medical technologies into healthcare services [1][2]. Group 1: Pricing Guidelines and Projects - The National Healthcare Security Administration has accelerated the compilation and issuance of medical service pricing project guidelines, having released a total of 36 batches, with provinces averaging 30 batches implemented [1]. - The 37th batch of guidelines includes 37 pricing projects specifically for surgical and treatment assistance operations, along with 5 additional charge items and 1 expansion item, covering key technologies such as 3D printing, intraoperative guidance, and surgical robotic arms [1][2]. Group 2: Focus on Surgical Robots - The pricing guidelines focus on the participation level of surgical robots in operations and their clinical value in precision surgery, categorizing pricing into navigation, execution participation, and precision execution [2]. - A coefficient-based charging model is implemented, allowing surgical robots with higher participation, comprehensive functions, and precise execution to receive higher fee coefficients [2]. Group 3: Remote Surgery and Resource Allocation - The establishment of the "remote surgical assistance fee" pricing project aims to facilitate remote surgeries conducted by experts in resource-rich areas for patients in other regions, thereby reducing the burden of travel for patients seeking quality medical care [2]. - The National Healthcare Security Administration is closely monitoring innovations in the medical industry and has unified over a hundred prospective pricing projects related to new technologies and products, paving the way for gradual industrial upgrades and leading healthcare payment innovations [2].